A 22-plex chemiluminescent microarray for pneumococcal antibodies.

Area of Science:

• Immunology
• Vaccinology
• Biotechnology

Background:

• Pneumococcal polysaccharide (PnPs) vaccines are crucial for preventing pneumococcal disease.
• Accurate measurement of serotype-specific IgG antibody concentrations is essential for evaluating vaccine efficacy.
• Current methods like ELISA can be time-consuming and may not be suitable for high-throughput analysis.

Purpose of the Study:

• To develop and validate a chemiluminescent multiplexed microarray for simultaneous quantification of IgG antibodies to 22 pneumococcal serotypes.
• To compare the performance of the developed microarray with the established enzyme-linked immunosorbent assay (ELISA).
• To assess the microarray's ability to detect vaccine-induced antibody responses.

Main Methods:

• Development of a chemiluminescent multiplexed microarray assay capable of detecting IgG antibodies against 22 specific pneumococcal polysaccharide serotypes.
• Comparative analysis of the microarray against ELISA for nine selected serotypes, calculating correlation coefficients (r2).
• Evaluation of assay precision using interassay and intra-assay coefficients of variation and assessment of specificity through inhibition-of-binding studies.

Main Results:

• The microarray demonstrated high correlation with ELISA (r2 = 0.91–0.97) for the nine compared serotypes.
• The assay successfully detected significant increases (more than 4-fold) in antibody concentrations post-vaccination across all 22 serotypes.
• Excellent assay precision was observed, with mean interassay and intra-assay coefficients of variation of 7.6% and 6.0%, respectively.
• Inhibition studies confirmed high specificity, with >90% inhibition by homologous serotypes and <25% by heterologous serotypes.

Conclusions:

• The developed chemiluminescent multiplexed microarray is a highly accurate and reproducible method for quantifying IgG antibodies to 22 pneumococcal serotypes.
• This technology provides a robust and efficient alternative to ELISA for assessing immune responses to pneumococcal vaccines.
• The microarray's ability to simultaneously measure antibodies to multiple serotypes makes it valuable for vaccine efficacy studies and public health surveillance.